A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)
Latest Information Update: 20 Feb 2024
At a glance
- Drugs Denosumab (Primary)
- Indications Early breast cancer
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms D-CARE
- Sponsors Amgen
- 29 Jun 2021 Results of an analysis assessing the prespecified exploratory bone endpoints and post hoc subgroup analysis based on age (less than 50 and more than or equal to 50 years) and menopause status published in the Advances in Therapy
- 28 Aug 2018 This trial has been completed in France.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology